Literature DB >> 21933139

Muscle metabolism and exercise capacity in cachexia.

Volker Adams1, Stefan D Anker, Gerhard Schuler.   

Abstract

Cachexia is often associated with severe loss of skeletal muscle mass and a reduced energy metabolism. The maintenance of muscle mass can be generally regarded as a simple balance between protein synthesis and protein degradation. Several evidences are available in the current literature favoring a model in which myofilaments are released from the sarcomere by the action of calcium-activated calpains followed by the degradation of the myofilaments by the ubiquitin proteasome system. The initiation of the protein breakdown machinery is regulated by several factors like inflammatory cytokines, angiotensin II, insulin / insulin like growth factor 1 and reactive oxygen species. These factors also have the capability to influence PGC-1alpha activity, thereby regulating mitochondrial energy production. All these molecular alterations regulating muscle mass and energy production in the skeletal muscle finally leads to a reduction in exercise capacity in cachexia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21933139     DOI: 10.2174/138161211798357746

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  3 in total

1.  1-Sarcosine-angiotensin II infusion effects on food intake, weight loss, energy expenditure, and skeletal muscle UCP3 gene expression in a rat model.

Authors:  S A Cichello; R S Weisinger; J Schuijers; M Jois
Journal:  J Cachexia Sarcopenia Muscle       Date:  2014-03-11       Impact factor: 12.910

Review 2.  Disrupted Skeletal Muscle Mitochondrial Dynamics, Mitophagy, and Biogenesis during Cancer Cachexia: A Role for Inflammation.

Authors:  Brandon N VanderVeen; Dennis K Fix; James A Carson
Journal:  Oxid Med Cell Longev       Date:  2017-07-13       Impact factor: 6.543

3.  Proteomic profiling of skeletal and cardiac muscle in cancer cachexia: alterations in sarcomeric and mitochondrial protein expression.

Authors:  Angie M Y Shum; Anne Poljak; Nicholas L Bentley; Nigel Turner; Timothy C Tan; Patsie Polly
Journal:  Oncotarget       Date:  2018-04-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.